19 May 2026 - Patients with neurofibromatosis are calling for insurance reimbursement to be expanded to adult patients for the targeted therapy Koselugo (selumetinib), which is currently covered only for paediatric and adolescent patients.

END NF, a patient advocacy group for neurofibromatosis, issued the appeal in conjunction with World Neurofibromatosis Awareness Day, stating, “It is the same drug, the same disease, and the same patients, yet once patients turn 18, the financial burden of treatment increases dozens of times.” The group urged authorities to extend reimbursement coverage to adult NF patients so they are not forced to abandon treatment due to overwhelming costs.

Read Korea Biomedical Review article